British drugmaker GlaxoSmithKline will sell the rights to several of its products in Australia to Aspen Pharmacare Holdings for nearly $US270 million ($258 million).
The company said on Wednesday that the deal involves 25 products it no longer promotes, including genital herpes treatment Valtrex and the antibiotics Timentin and Amoxil. Sydney Morning Herald – Read more…